文献速递白血病

利用光学基因组图谱优化急性淋巴细胞白血病的诊断流程

Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping.
PubMed 文献 · Am J Hematol · 2022-03-09

该研究将光学基因组图谱(OGM)应用于41例急性淋巴细胞白血病(ALL)的诊断流程,并与标准检测路径比较。OGM识别了全部可重现的拷贝数改变和结构变异,使32例患者可归入主要细胞遗传学风险组,而标准方法为23例。OGM提高了检出率和细胞遗传学分辨率,减少了级联检测需求并缩短了周转时间,但仍需联合染色体显带分析或SNP芯片检测倍性变化,以及BCR::ABL1 FISH以尽快分配靶向治疗患者。

要点

  • OGM识别了全部可重现的拷贝数改变和结构变异,标准方法识别24/34种可重现染色体异常,OGM识别33/34种。
  • 基于OGM的基因组谱可将32例患者归入主要细胞遗传学风险组,标准方法为23例。
  • OGM仍需联合染色体显带分析或SNP芯片检测倍性变化,以及BCR::ABL1 FISH分配靶向治疗。

核心结论

  • 与标准检测路径相比,OGM提高了检出率和细胞遗传学分辨率,减少了级联检测需求并缩短了周转时间,为更好的患者分层和准确的治疗选择提供了机会。
  • 为进行全面细胞基因组检测,OGM仍需联合染色体显带分析或SNP芯片以检测倍性变化,并联合BCR::ABL1 FISH以及早将患者分配至靶向治疗。

研究设计与样本

  • 研究将光学基因组图谱(OGM)应用于41例急性淋巴细胞白血病(ALL)病例的诊断流程,并与本中心标准检测路径进行比较。

主要发现

  • 与标准检测路径相比,OGM识别了全部可重现的拷贝数改变和结构变异,以及额外的可重现结构变异和由此产生的融合基因。
  • 基于OGM获得的基因组谱,32例患者可被归入主要细胞遗传学风险组之一,而标准方法为23例。
  • 标准方法识别了24/34种可重现染色体异常,OGM识别了33/34种,仅1例低超二倍体病例被误判。
  • MLPA结果在100%的病例中一致,总体而言两种方法结果之间具有极好的一致性。

临床怎么用

  • 作者指出,OGM提高了检出率和细胞遗传学分辨率,减少了级联检测需求并缩短了周转时间,为更好的患者分层和准确的治疗选择提供了机会。
  • 作者指出,为进行全面细胞基因组检测,OGM仍需联合染色体显带分析或SNP芯片以检测倍性变化,并联合BCR::ABL1 FISH以及早将患者分配至靶向治疗。

局限性

  • OGM仅1例低超二倍体病例被误判。
  • 为进行全面细胞基因组检测,OGM仍需联合染色体显带分析或SNP芯片以检测倍性变化,并联合BCR::ABL1 FISH以及早将患者分配至靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute lymphoblastic leukemia (ALL) is a malignancy that can be subdivided into distinct entities based on clinical, immunophenotypic and genomic features, including mutations, structural variants (SVs), and copy number alterations (CNA). Chromosome banding analysis (CBA) and Fluorescent In-Situ Hybridization (FISH) together with Multiple Ligation-dependent Probe Amplification (MLPA), array and PCR-based methods form the backbone of routine diagnostics. This approach is labor-intensive, time-consuming and costly. New molecular technologies now exist that can detect SVs and CNAs in one test. Here we apply one such technology, optical genome mapping (OGM), to the diagnostic work-up of 41 ALL cases. Compared to our standard testing pathway, OGM identified all recurrent CNAs and SVs as well as additional recurrent SVs and the resulting fusion genes. Based on the genomic profile obtained by OGM, 32 patients could be assigned to one of the major cytogenetic risk groups compared to 23 with the standard approach. The latter identified 24/34 recurrent chromosomal abnormalities, while OGM identified 33/34, misinterpreting only 1 case with low hypodiploidy. The results of MLPA were concordant in 100% of cases. Overall, there was excellent concordance between the results. OGM increased the detection rate and cytogenetic resolution, and abrogated the need for cascade testing, resulting in reduced turnaround times. OGM also provided opportunities for better patient stratification and accurate treatment options. However, for comprehensive cytogenomic testing, OGM still needs to be complemented with CBA or SNP-array to detect ploidy changes and with BCR::ABL1 FISH to assign patients as soon as possible to targeted therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rack K, De Bie J, Ameye G, et al. Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping. Am J Hematol. 2022. PMID: 35119131. doi:10.1002/ajh.26487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。